Wire · opportunities
FDA Panel Backs Six Popular Peptides for Pharmacy Use, but They Are Not Approved Yet
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
An FDA advisory committee voted to recommend six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) for inclusion on the federal 503A compounding list, allowing licensed pharmacies to prepare them for individual patients with prescriptions, though the FDA has not yet made a final decision and the substances remain unapproved for general use.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
If the FDA accepts this recommendation, you've just got a legal distribution channel for peptides that currently only exist in the grey market. That's not approval - it's a pharmacy-only prescription route - but it's the first regulatory door open for compounds your customers are already buying unsafely online.
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics